GSK plc (NYSE:GSK) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in GSK plc (NYSE:GSK - Free Report) by 14.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,293 shares of the pharmaceutical company's stock after selling 7,310 shares during the period. Nuveen Asset Management LLC's holdings in GSK were worth $1,430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of GSK. Dorsey & Whitney Trust CO LLC raised its holdings in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after purchasing an additional 278 shares during the period. GC Wealth Management RIA LLC grew its position in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after acquiring an additional 353 shares in the last quarter. Jacobi Capital Management LLC grew its position in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after acquiring an additional 389 shares in the last quarter. Gladstone Institutional Advisory LLC grew its stake in shares of GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after buying an additional 407 shares during the last quarter. Finally, CENTRAL TRUST Co grew its stake in shares of GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock valued at $262,000 after buying an additional 414 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. BNP Paribas assumed coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Morgan Stanley initiated coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $37.38.

GSK Stock Up 0.8%

NYSE:GSK traded up $0.31 during trading hours on Thursday, reaching $41.11. The company's stock had a trading volume of 3,247,422 shares, compared to its average volume of 4,830,246. The company has a market capitalization of $84.82 billion, a P/E ratio of 25.86, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a 12 month low of $31.72 and a 12 month high of $44.67. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a 50 day moving average price of $37.48 and a two-hundred day moving average price of $36.28.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.43 earnings per share. Equities analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.10%. GSK's payout ratio is 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.